KIMS Q4 Earnings Surge: Hospital Chain Expands Dominance

Revenue jumped 22% year-over-year to ₹850 crore, driven by a 15% increase in average revenue per occupied bed. EBITDA margins expanded to 28%, up from 24% in the prior year, reflecting operational leverage from new facilities. The company added 500 beds during the quarter, with plans for 1,000 more in FY2027.

Management cited strong demand in oncology and cardiology as key growth drivers, with these specialties contributing 40% of revenue. The acquisition of a 300-bed hospital in Pune is expected to close in Q1, further strengthening KIMS's presence in western India. Cash flow from operations reached ₹180 crore, enabling debt reduction.

Analysts note KIMS's focus on tier-2 and tier-3 cities provides a competitive moat against urban-centric rivals. The company's asset-light expansion model, using long-term leases, minimizes capital expenditure while maximizing returns. With India's healthcare spending projected to grow at 12% CAGR, KIMS is well-positioned to capture market share.

Power Move: KIMS is executing a textbook growth strategy: expand capacity, optimize operations, and enter underserved markets. Expect the stock to outperform as earnings momentum continues. The real power move lies in its ability to replicate this model across India's fragmented hospital landscape.

This article was edited with AI assistance for readability. Read original here.